

(PRE-FILED)

By: **The Speaker and Delegates Rosenberg, Conway, and Hixson**

Requested: November 9, 2005

Introduced and read first time: January 11, 2006

Assigned to: Health and Government Operations and Appropriations

A BILL ENTITLED

1 AN ACT concerning

2 **Maryland Stem Cell Research Act of 2006**

3 FOR the purpose of requiring certain persons to conduct certain research in a certain
4 manner; establishing the Maryland Stem Cell Research Fund; providing for the
5 purpose of the Fund; specifying that the Fund is a special, nonlapsing fund;
6 specifying that the State Treasurer shall hold the Fund separately and that the
7 Comptroller shall account for the Fund; specifying that certain proceeds shall be
8 invested and reinvested in a certain manner; specifying that certain earnings
9 shall be paid into the Fund; providing for the composition of the Fund; requiring
10 the Department of Health and Mental Hygiene to administer the Fund;
11 providing that money in the Fund may only be used for certain purposes;
12 requiring the Secretary of Health and Mental Hygiene to adopt certain
13 regulations; establishing the Maryland Scientific Peer Review Committee;
14 requiring the Committee to establish certain procedures, ensure that these
15 procedures are based on certain guidelines, develop and implement a certain
16 ranking and rating system, and make certain recommendations; providing for
17 the membership of the Committee; authorizing the Committee to invite certain
18 experts and certain consultants to certain meetings; requiring the Committee to
19 select a certain chair; providing for the filling of certain vacancies; requiring the
20 members of the Committee to make certain disclosures to the State Commission
21 on Ethics; requiring the Committee to meet at certain times in certain places;
22 requiring the Department to provide staff for the Committee; establishing the
23 Stem Cell Research Commission in the Department; providing for the
24 membership of the Commission; requiring the Governor to designate the chair of
25 the Commission; requiring the Department to provide staff for the Commission;
26 providing for the terms of certain members of the Commission; requiring the
27 members of the Commission to make certain disclosures to the State
28 Commission on Ethics; requiring the Commission to carry out certain functions
29 and duties; requiring the Commission to meet at certain times; providing for
30 certain contingencies; requiring a grantee to submit a certain approval;
31 prohibiting the Department from disbursing certain money under certain
32 circumstances; requiring certain health care practitioners to provide certain
33 individuals with certain information; requiring certain individuals to provide
34 certain consent to certain donations; providing that certain provisions of law

may not be construed to prohibit the creation of certain stem cell lines to be used for certain purposes; prohibiting the purchase, sale, transfer, or obtaining of human embryos for valuable consideration; prohibiting the encouragement of the production of human embryos for certain research; prohibiting human cloning; providing for certain penalties; defining certain terms; requiring the Governor to include a certain appropriation in the annual budget bill; requiring certain reports; providing for the staggering of certain terms; and generally relating to State-funded stem cell research.

9 BY adding to

Article - Health - General

Section 20-1101 through 20-1111, inclusive, to be under the new subtitle

"Subtitle 11. Stem Cell Research"

Annotated Code of Maryland

(2005 Replacement Volume and 2005 Supplement)

Preamble

WHEREAS, An estimated 128,000,000 Americans suffer from the crippling physical, economic, and psychological burdens of chronic, degenerative, and acute diseases, including Alzheimer's disease, heart disease, diabetes, Parkinson's disease, spinal cord injuries, macular degeneration, ALS, multiple sclerosis, and cancer; and

WHEREAS, The costs of treatment and lost productivity of chronic, degenerative, and acute diseases in the United States constitute hundreds of billions of dollars every year, and estimates of the economic costs of these diseases do not account for the extreme human loss and suffering associated with these conditions; and

WHEREAS, Stem cell research offers immense promise for developing new medical therapies and a better understanding of these debilitating diseases and could lead to unprecedented treatments and potential cures for Alzheimer's disease, heart disease, diabetes, Parkinson's disease, cancer, and other diseases; and

WHEREAS, Approximately half of Maryland's families have a family member who has or will suffer from a serious, often critical or terminal, medical condition that could potentially be treated or cured with medical therapies derived from stem cell research; and

WHEREAS, Maryland's current health care system may not be able to meet the needs of these individuals in the future unless medical care can focus on early diagnosis, cure, and prevention rather than palliation of late-stage effects of the disease; and

WHEREAS, The United States and the State of Maryland have historically fostered open scientific inquiry and technological innovation, and this environment, coupled with the commitment of public and private resources, has made the United States the preeminent world leader in biomedicine and biotechnology; and

1 WHEREAS, Maryland ranks as the fourth-largest sector for biotechnology
2 companies in the nation; and

3 WHEREAS, The biotechnology industry is a key component of the State's
4 economy that provides employment in over 300 companies, many of which engage in
5 some form of stem cell research; and

6 WHEREAS, The University of Maryland, Baltimore and The Johns Hopkins
7 University are involved in stem cell research, with projects representing a combined
8 total of approximately \$10,000,000 in public and private funding; and

9 WHEREAS, The State's favorable research climate would be significantly
10 diminished by limitations imposed on stem cell research; and

11 WHEREAS, Stem cell research, including the use of embryonic stem cells for
12 medical research, raises significant ethical and policy concerns that must be carefully
13 considered; and

14 WHEREAS, Public policy on stem cell research must balance ethical and
15 medical considerations and must be based on an understanding of the science
16 associated with stem cell research while grounded on a thorough consideration of the
17 ethical concerns; and

18 WHEREAS, Stem cell research must be carefully crafted to ensure that
19 researchers have the tools necessary to fulfill the promise of stem cell research; now,
20 therefore,

21 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
22 MARYLAND, That the Laws of Maryland read as follows:

23 **Article - Health - General**

24 **SUBTITLE 11. STEM CELL RESEARCH.**

25 20-1101.

26 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS
27 INDICATED.

28 (B) "COMMISSION" MEANS THE STEM CELL RESEARCH COMMISSION IN THE
29 DEPARTMENT.

30 (C) "COMMITTEE" MEANS THE MARYLAND SCIENTIFIC PEER REVIEW
31 COMMITTEE.

32 (D) "EMBRYO" MEANS THE STAGE BETWEEN THE OVUM AND THE FETUS IN
33 PRENATAL DEVELOPMENT.

34 (E) "FUND" MEANS THE MARYLAND STEM CELL RESEARCH FUND.

1 (F) "HUMAN CLONING" MEANS THE REPLICATION OF A HUMAN BEING
2 THROUGH THE PRODUCTION OF A PRECISE GENETIC COPY OF HUMAN DNA OR ANY
3 OTHER HUMAN MOLECULE, CELL, OR TISSUE, IN ORDER TO CREATE A NEW HUMAN
4 BEING.

5 (G) "INSTITUTIONAL REVIEW BOARD" HAS THE MEANING STATED IN THE
6 FEDERAL REGULATIONS ON THE PROTECTION OF HUMAN SUBJECTS.

7 (H) "STATE-FUNDED STEM CELL RESEARCH" MEANS STEM CELL RESEARCH
8 CONDUCTED USING DONATED UNUSED HUMAN EMBRYOS WHICH WERE CREATED
9 FOR INDIVIDUALS BEING TREATED FOR INFERTILITY AND FOR WHICH A GRANT
10 FROM THE FUND IS SOUGHT OR AWARDED.

11 (I) "STEM CELL" MEANS A CELL THAT HAS THE ABILITY TO:

12 (1) DIVIDE;

13 (2) GIVE RISE TO SPECIALIZED CELLS; AND

14 (3) GIVE RISE TO NEW STEM CELLS WITH IDENTICAL POTENTIAL.

15 (J) (1) "VALUABLE CONSIDERATION" MEANS FINANCIAL GAIN OR
16 ADVANTAGE.

17 (2) "VALUABLE CONSIDERATION" DOES NOT INCLUDE REASONABLE
18 PAYMENT FOR THE REMOVAL, PROCESSING, DISPOSAL, PRESERVATION, QUALITY
19 CONTROL, STORAGE, TRANSPLANTATION, OR GRAFTING OF EMBRYONIC OR
20 CADAVERIC FETAL TISSUE.

21 20-1102.

22 A PERSON WHO CONDUCTS STATE-FUNDED STEM CELL RESEARCH SHALL
23 CONDUCT THE RESEARCH IN A MANNER THAT CONSIDERS THE ETHICAL AND
24 MEDICAL IMPLICATIONS OF THE RESEARCH.

25 20-1103.

26 (A) THERE IS A MARYLAND STEM CELL RESEARCH FUND.

27 (B) THE PURPOSE OF THE FUND IS TO PROMOTE STATE-FUNDED STEM CELL
28 RESEARCH AND CURES THROUGH GRANTS AND LOANS TO PUBLIC AND PRIVATE
29 ENTITIES IN THE STATE.

30 (C) THE FUND IS A SPECIAL, NONLAPSING FUND THAT IS NOT SUBJECT TO §
31 7-302 OF THE STATE FINANCE AND PROCUREMENT ARTICLE.

32 (D) THE STATE TREASURER SHALL HOLD THE FUND AND THE COMPTROLLER
33 SHALL ACCOUNT FOR THE FUND.

34 (E) THE PROCEEDS OF THE FUND SHALL BE INVESTED AND REINVESTED IN
35 THE SAME MANNER AS OTHER STATE FUNDS.

1 (F) ANY INVESTMENT EARNINGS SHALL BE PAID INTO THE FUND.

2 (G) THE FUND CONSISTS OF:

3 (1) AN APPROPRIATION EQUAL TO AT LEAST \$25,000,000 AS PROVIDED IN
4 THE STATE BUDGET; AND

5 (2) ANY OTHER MONEY FROM ANY OTHER SOURCE ACCEPTED FOR THE
6 BENEFIT OF THE FUND.

7 (H) THE DEPARTMENT SHALL ADMINISTER THE FUND.

8 (I) MONEY IN THE FUND MAY ONLY BE EXPENDED TO:

9 (1) AWARD GRANTS AND LOANS FOR STATE-FUNDED STEM CELL
10 RESEARCH;

11 (2) AWARD GRANTS AND LOANS FOR FACILITIES, CAPITAL LEASES, AND
12 CAPITAL EQUIPMENT WHERE STATE-FUNDED STEM CELL RESEARCH IS
13 CONDUCTED; AND

14 (3) PAY THE COSTS NECESSARY TO ADMINISTER THE FUND.

15 (J) EXPENDITURES FROM THE FUND MAY ONLY BE MADE IN ACCORDANCE
16 WITH AN APPROPRIATION APPROVED BY THE GENERAL ASSEMBLY IN THE ANNUAL
17 STATE BUDGET OR BY AN APPROVED BUDGET AMENDMENT.

18 (K) THE SECRETARY, IN CONSULTATION WITH THE COMMISSION, SHALL
19 ADOPT REGULATIONS TO CARRY OUT THE PROVISIONS OF THIS SECTION,
20 INCLUDING:

21 (1) CRITERIA, STANDARDS, AND REQUIREMENTS FOR FUNDING
22 APPLICATIONS AND THE AWARD OF GRANTS AND LOANS FROM THE FUND;

23 (2) PROCEDURES FOR MAKING THE DISBURSEMENT OF A GRANT
24 CONTINGENT ON OBTAINMENT OF THE APPROVAL OF AN INSTITUTIONAL REVIEW
25 BOARD; AND

26 (3) STANDARDS FOR THE OVERSIGHT OF USE OF AWARDS.

27 20-1104.

28 (A) THERE IS A MARYLAND SCIENTIFIC PEER REVIEW COMMITTEE.

29 (B) THE COMMITTEE SHALL:

30 (1) ESTABLISH PROCEDURES FOR THE REVIEW OF RESEARCH
31 PROPOSALS FOR STATE-FUNDED STEM CELL RESEARCH;

1 (2) ENSURE THAT THE PROCEDURES ESTABLISHED UNDER ITEM (1) OF
2 THIS SUBSECTION ARE BASED ON THE GUIDELINES OF THE FEDERAL NATIONAL
3 INSTITUTES OF HEALTH'S CENTER FOR SCIENTIFIC REVIEW;

4 (3) DEVELOP AND IMPLEMENT A RANKING AND RATING SYSTEM
5 THROUGH WHICH AN OBJECTIVE ASSESSMENT MAY BE MADE OF RESEARCH
6 PROPOSALS REVIEWED UNDER ITEM (1) OF THIS SUBSECTION; AND

7 (4) MAKE RECOMMENDATIONS TO THE COMMISSION, BASED ON THE
8 RANKINGS AND RATINGS AWARDED TO RESEARCH PROPOSALS UNDER ITEM (3) OF
9 THIS SUBSECTION, FOR THE AWARD AND DISBURSEMENT OF GRANTS UNDER THE
10 FUND.

11 (C) (1) THE COMMITTEE SHALL CONSIST OF THE FOLLOWING MEMBERS
12 SELECTED FROM THE SCIENTIFIC COMMUNITY:

13 (I) TWO SHALL BE SELECTED BY THE SECRETARY;

14 (II) TWO SHALL BE SELECTED BY THE SECRETARY OF BUSINESS
15 AND ECONOMIC DEVELOPMENT;

16 (III) TWO SHALL BE SELECTED BY THE JOHNS HOPKINS
17 UNIVERSITY;

18 (IV) TWO SHALL BE SELECTED BY THE UNIVERSITY SYSTEM OF
19 MARYLAND; AND

20 (V) TWO SHALL BE SELECTED BY THE MARYLAND BIOSCIENCE
21 ALLIANCE.

22 (2) THE MEMBERS OF THE COMMITTEE SELECTED UNDER PARAGRAPH
23 (1) OF THIS SUBSECTION MAY BE FROM OUT OF STATE.

24 (3) THE COMMITTEE MAY INVITE EXPERTS AND CONSULTANTS TO
25 ATTEND MEETINGS OF THE COMMITTEE.

26 (D) THE COMMITTEE SHALL SELECT A CHAIR FROM AMONG ITS MEMBERS.

27 (E) A VACANCY ON THE COMMITTEE SHALL BE FILLED BY THE PERSON
28 UNDER SUBSECTION (C)(1) OF THIS SECTION WHO HAD SELECTED THE FORMER
29 MEMBER OF THE COMMITTEE.

30 (F) EACH MEMBER OF THE COMMITTEE SHALL DISCLOSE TO THE STATE
31 COMMISSION ON ETHICS WHETHER THE MEMBER IS EMPLOYED BY OR HAS A
32 FINANCIAL INTEREST IN AN ENTITY THAT MAY APPLY TO CONDUCT STATE-FUNDED
33 STEM CELL RESEARCH.

34 (G) THE COMMITTEE SHALL MEET AT LEAST TWICE EACH YEAR, AT THE
35 TIMES AND PLACES THAT IT DETERMINES.

36 (H) THE DEPARTMENT SHALL PROVIDE STAFF FOR THE COMMITTEE.

1 20-1105.

2 (A) THERE IS A STEM CELL RESEARCH COMMISSION IN THE DEPARTMENT.

3 (B) THE COMMISSION CONSISTS OF THE FOLLOWING MEMBERS:

4 (1) THE SECRETARY OR THE SECRETARY'S DESIGNEE;

5 (2) THE ATTORNEY GENERAL OR THE ATTORNEY GENERAL'S DESIGNEE;

6 (3) THE SECRETARY OF BUSINESS AND ECONOMIC DEVELOPMENT OR
7 THE SECRETARY'S DESIGNEE;

8 (4) THE STATE TREASURER OR THE TREASURER'S DESIGNEE;

9 (5) THE COMPTROLLER OR THE COMPTROLLER'S DESIGNEE; AND

10 (6) THE FOLLOWING MEMBERS APPOINTED BY THE GOVERNOR:

11 (I) TWO WITH EXPERTISE IN THE FIELD OF BIOMEDICAL ETHICS;

12 (II) ONE WITH EXPERTISE IN THE FIELD OF BIOMEDICAL ETHICS
13 AS IT RELATES TO RELIGION;

14 (III) ONE WHO WORKS AS A SCIENTIST AND ENGAGES IN STEM CELL
15 RESEARCH FOR THE UNIVERSITY SYSTEM OF MARYLAND;

16 (IV) ONE WHO WORKS AS A SCIENTIST AND ENGAGES IN STEM CELL
17 RESEARCH FOR THE JOHNS HOPKINS UNIVERSITY;

18 (V) ONE FROM THE MARYLAND BIOSCIENCE ALLIANCE; AND

19 (VI) TWO CONSUMER MEMBERS.

20 (C) THE GOVERNOR SHALL DESIGNATE THE CHAIR OF THE COMMISSION.

21 (D) THE DEPARTMENT SHALL PROVIDE STAFF FOR THE COMMISSION.

22 (E) (1) THE TERM OF AN APPOINTED MEMBER IS 4 YEARS.

23 (2) THE TERMS OF THE APPOINTED MEMBERS ARE STAGGERED AS
24 REQUIRED BY THE TERMS PROVIDED FOR MEMBERS ON OCTOBER 1, 2006.

25 (3) AT THE END OF A TERM, AN APPOINTED MEMBER CONTINUES TO
26 SERVE UNTIL A SUCCESSOR IS APPOINTED AND QUALIFIES.

27 (4) AN APPOINTED MEMBER MAY NOT SERVE MORE THAN TWO
28 CONSECUTIVE FULL TERMS.

1 (5) AN APPOINTED MEMBER WHO IS APPOINTED AFTER A TERM HAS
2 BEGUN SERVES ONLY FOR THE REST OF THE TERM AND UNTIL A SUCCESSOR IS
3 APPOINTED AND QUALIFIES.

4 (F) EACH MEMBER OF THE COMMISSION SHALL DISCLOSE TO THE STATE
5 COMMISSION ON ETHICS WHETHER THE MEMBER IS EMPLOYED BY OR HAS A
6 FINANCIAL INTEREST IN AN ENTITY THAT MAY APPLY TO CONDUCT STATE-FUNDED
7 STEM CELL RESEARCH.

8 20-1106.

9 (A) THE COMMISSION SHALL:

10 (1) ADOPT REGULATIONS THAT ENSURE THAT STEM CELL RESEARCH
11 FINANCED BY THE FUND COMPLIES WITH STATE LAW;

12 (2) RECOMMEND TO THE SECRETARY:

13 (I) CRITERIA, STANDARDS, AND REQUIREMENTS FOR
14 CONSIDERATION OF FUNDING APPLICATIONS BASED ON THE RANKINGS AND
15 RATINGS OF THE COMMITTEE; AND

16 (II) STANDARDS FOR THE OVERSIGHT OF USE OF AWARDS;

17 (3) REVIEW GRANT AND LOAN APPLICATIONS BASED ON CRITERIA AND
18 STANDARDS ADOPTED BY THE SECRETARY;

19 (4) MAKE RECOMMENDATIONS CONSISTENT WITH THE CRITERIA AND
20 STANDARDS ADOPTED BY THE SECRETARY AND BASED SOLELY ON THE RANKINGS
21 AND RATINGS OF THE COMMITTEE REGARDING THE AWARD OF GRANTS AND LOANS
22 FROM THE FUND;

23 (5) NOTIFY THE SECRETARY REGARDING THE SUBMISSION BY A
24 GRANTEE, OR FAILURE OF A GRANTEE, TO SUBMIT INSTITUTIONAL REVIEW BOARD
25 APPROVAL FOR A GRANT AWARDED UNDER THIS SUBTITLE; AND

26 (6) CONDUCT PROGRESS OVERSIGHT REVIEWS OF GRANTEES.

27 (B) THE COMMISSION SHALL MEET AT LEAST TWICE A YEAR.

28 20-1107.

29 (A) A GRANT AWARDED UNDER THIS SUBTITLE SHALL BE CONTINGENT ON:

30 (1) THE SUBMISSION BY A GRANTEE TO THE COMMISSION OF APPROVAL
31 FROM AN INSTITUTIONAL REVIEW BOARD; AND

32 (2) ENTRANCE INTO A MEMORANDUM OF UNDERSTANDING BETWEEN
33 THE GRANTEE AND THE DEPARTMENT THAT:

1 (I) ESTABLISHES THE SCOPE OF THE STATE'S OWNERSHIP OR
2 OTHER FINANCIAL INTEREST IN THE COMMERCIALIZATION AND OTHER BENEFITS
3 OF THE RESULTS, PRODUCTS, INVENTIONS, AND DISCOVERIES OF STATE-FUNDED
4 STEM CELL RESEARCH; AND

5 (II) TO THE EXTENT CONSISTENT WITH FEDERAL AND STATE LAW,
6 REFLECTS THE INTELLECTUAL PROPERTY POLICIES OF THE INSTITUTION.

7 (B) A GRANTEE SHALL SUBMIT THE APPROVAL REQUIRED UNDER
8 SUBSECTION (A)(1) OF THIS SECTION WITHIN 6 MONTHS OF THE AWARD OF THE
9 GRANT.

10 (C) THE DEPARTMENT MAY NOT DISBURSE GRANT MONEY TO A GRANTEE
11 UNTIL:

12 (1) THE APPROVAL REQUIRED UNDER THIS SECTION HAS BEEN
13 OBTAINED; AND

14 (2) THE MEMORANDUM OF UNDERSTANDING REQUIRED UNDER
15 SUBSECTION (A)(2) OF THIS SECTION HAS BEEN OBTAINED.

16 20-1108.

17 (A) A HEALTH CARE PRACTITIONER LICENSED UNDER THE HEALTH
18 OCCUPATIONS ARTICLE WHO TREATS INDIVIDUALS FOR INFERTILITY SHALL:

19 (1) PROVIDE INDIVIDUALS WITH INFORMATION SUFFICIENT TO ENABLE
20 THEM TO MAKE AN INFORMED AND VOLUNTARY CHOICE REGARDING THE
21 DISPOSITION OF HUMAN EMBRYOS; AND

22 (2) PRESENT TO INDIVIDUALS THE OPTION OF:

23 (I) STORING OR DISCARDING UNUSED HUMAN EMBRYOS;

24 (II) DONATING UNUSED HUMAN EMBRYOS FOR CLINICAL
25 PURPOSES IN THE TREATMENT OF INFERTILITY;

26 (III) DONATING UNUSED HUMAN EMBRYOS FOR RESEARCH
27 PURPOSES; AND

28 (IV) DONATING UNUSED HUMAN EMBRYOS FOR EMBRYO ADOPTION
29 PURPOSES.

30 (B) AN INDIVIDUAL WHO DONATES UNUSED HUMAN EMBRYOS FOR
31 RESEARCH PURPOSES UNDER SUBSECTION (A)(2) OF THIS SECTION SHALL PROVIDE
32 THE HEALTH CARE PRACTITIONER WITH WRITTEN CONSENT FOR THE DONATION.

1 20-1109.

2 NOTHING IN THIS SUBTITLE SHALL BE CONSTRUED TO PROHIBIT THE
3 CREATION OF STEM CELL LINES TO BE USED FOR THERAPEUTIC RESEARCH
4 PURPOSES.

5 20-1110.

6 (A) A PERSON MAY NOT PURCHASE, SELL, TRANSFER, OR OBTAIN HUMAN
7 EMBRYOS FOR VALUABLE CONSIDERATION UNDER THIS SUBTITLE.

8 (B) A PERSON MAY NOT GIVE VALUABLE CONSIDERATION TO ANOTHER
9 PERSON TO ENCOURAGE THE PRODUCTION OF HUMAN EMBRYOS FOR THE SOLE
10 PURPOSE OF MEDICAL RESEARCH.

11 (C) A PERSON WHO VIOLATES THIS SECTION IS GUILTY OF A MISDEMEANOR
12 AND ON CONVICTION IS SUBJECT TO IMPRISONMENT NOT EXCEEDING 3 YEARS OR A
13 FINE NOT EXCEEDING \$50,000 OR BOTH.

14 20-1111.

15 (A) A PERSON MAY NOT CONDUCT OR ATTEMPT TO CONDUCT HUMAN
16 CLONING.

17 (B) A PERSON WHO VIOLATES THIS SECTION IS GUILTY OF A FELONY AND ON
18 CONVICTION IS SUBJECT TO IMPRISONMENT NOT EXCEEDING 10 YEARS OR A FINE
19 NOT EXCEEDING \$200,000 OR BOTH.

20 SECTION 2. AND BE IT FURTHER ENACTED, That for fiscal year 2008 and
21 each fiscal year thereafter, the Governor shall include in the annual budget bill an
22 appropriation equal to at least \$25,000,000 to the stem cell research fund established
23 under Title 20, Subtitle 11 of the Health - General Article.

24 SECTION 3. AND BE IT FURTHER ENACTED, That the Department of
25 Health and Mental Hygiene and the Stem Cell Research Commission shall report to
26 the Governor and the General Assembly on or before January 1 of each year, in
27 accordance with § 2-1246 of the State Government Article, regarding the progress of
28 State-funded stem cell research conducted in accordance with this Act.

29 SECTION 4. AND BE IT FURTHER ENACTED, That the terms of the members
30 of the Stem Cell Research Commission appointed by the Governor shall expire as
31 follows:

32 (1) three in 2008;

33 (2) three in 2009; and

34 (3) two in 2010.

35 SECTION 5. AND BE IT FURTHER ENACTED, That this Act shall take effect
36 October 1, 2006.

